Alterations of eicosanoids and related mediators in patients with schizophrenia

Wang, Dongfang; Sun, Xiaoyu; Yan, Jingjing; Ren, Biao; Cao, Bing; Lu, Qing‐Bin; Liu, Yaqiong; Zeng, Jing; Huang, Ninghua; Xie, Qing; Gu, Haiwei; Wang, Jingyu

doi:10.1016/j.jpsychires.2018.04.002

Cited by 23 publications

(12 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As mentioned above, patients with schizophrenia exhibit higher sEH protein levels in the parietal cortex than controls. Meanwhile, another study investigating alterations of eicosanoids in the serum of patients with schizophrenia reported that 11,12-DHETs and 14,15-DHETs were increased in patients compared with controls and were decreased post-treatment (Wang et al., 2018). This evidence suggested that EET and its metabolic enzyme sEH may play a role in schizophrenia, and studies using animal models have provided strong supportive data.…”

Section: Role Of Seh In Psychiatric Disordersmentioning

confidence: 99%

Soluble Epoxide Hydrolase Inhibitor: A Novel Potential Therapeutic or Prophylactic Drug for Psychiatric Disorders

Ren

2019

Front. Pharmacol.

View full text Add to dashboard Cite

Psychiatric disorders, including depression and schizophrenia, affect millions of individuals worldwide. However, the precise neurobiology of psychiatric disorders remains unclear. Accumulating evidence suggests that various inflammatory processes play a key role in depression and schizophrenia, and that anti-inflammatory drugs exert a therapeutic effect in patients with psychiatric disorders. Epoxyeicosatrienoic acids (EETs) and epoxydocosapentaenoic acids (EDPs) have potent anti-inflammatory properties. These mediators are broken down into their corresponding diols by soluble epoxide hydrolase (sEH), and inhibition of sEH enhances the anti-inflammatory effects of EETs. Therefore, sEH may play a key role in inflammation, which is involved in psychiatric disorders. Recent studies have shown that abnormal levels of sEH may be involved in the pathogenesis of certain psychiatric diseases, and that sEH inhibitors exhibit antidepressant and antipsychotic activity. The present review discusses the extensive evidence supporting sEH as a therapeutic target for psychiatric diseases, and the clinical value of sEH inhibitors as therapeutic or prophylactic drugs.

show abstract

Section: Role Of Seh In Psychiatric Disordersmentioning

confidence: 99%

Soluble Epoxide Hydrolase Inhibitor: A Novel Potential Therapeutic or Prophylactic Drug for Psychiatric Disorders

Ren

2019

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Bioactive lipid mediators are a class of under-appreciated, under-utilized molecules in studies of inflammation. Specifically, the bioactive metabolites derived from fatty acids, termed eicosanoids, participate in modulation of inflammation [57,58] and pain [59], and have been shown to affect risks of hypertension [60], cardiovascular diseases [61], cancer [62], anorexia nervosa [63], and schizophrenia [64]. To more comprehensively assess how dietary-based intervention [65] may affect inflammation and psychiatric outcomes [66][67][68], MS technology has been extended to lipidomics analysis for polyunsaturated fatty acids (PUFA) [69,70].…”

Section: Polyunsaturated Fatty Acids In Psychiatric Disordersmentioning

confidence: 99%

“…Almost 40 years later, the field can now take advantage of both untargeted and targeted liquid chromatography-mass spectrometry-based methods to monitor a much larger number of potential markers. A recent schizophrenia study that investigated 158 markers including PUFA, eicosanoids, and related mediators from enzyme-dependent or independent pathways uncovered 23 metabolites that were significantly altered in patients compared with healthy controls [64]. While some abnormal markers were reversed after antipsychotic treatment, anandamide, oleoylethanolamine, and ARA were identified as having the best potential for differentiating patients from controls [64].…”

Section: Eicosanoids As Biomarkers For Psychiatric Disordersmentioning

confidence: 99%

Metabolomics Biomarkers for Precision Psychiatry

Shih

2019

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

The treatment of psychiatric disorders remains a significant challenge in part due to imprecise diagnostic criteria and incomplete understanding of the molecular pathology involved. Current diagnostic and pharmacological treatment guidelines use a uniform approach to address each disorder even though psychiatric clinical presentation and prognosis within a disorder are known to be heterogeneous. Limited therapeutic success highlights the need for a precision medicine approach in psychiatry, termed precision psychiatry. To practice precision psychiatry, it is essential to research and develop multiple omics-based biomarkers that consider environmental factors and careful phenotype determination. Metabolomics, which lies at the endpoint of the "omics cascade," allows for detection of alterations in systems-level metabolites within biological pathways, thereby providing insights into the mechanisms that underlie various physiological conditions and pathologies. The eicosanoids, a family of metabolites derived from oxygenated polyunsaturated fatty acids, play a key role in inflammatory mechanisms and have been implicated in psychiatric disorders such as anorexia nervosa and depression. This review (1) provides background on the current clinical challenges of psychiatric disorders, (2) gives an overview of metabolomics application as a tool to develop improved biomarkers for precision psychiatry, and (3) summarizes current knowledge on metabolomics and lipidomic findings in common psychiatric disorders, with a focus on eicosanoids. Metabolomics is a promising tool for precision psychiatry. This research has great potential for both discovering biomarkers and elucidating molecular mechanisms underlying psychiatric disorders.

show abstract

“…They observed a significant increase in anandamide (AEA) and oleoylethanolamine (OEA) concentrations and selected them as biomarkers in SCZ patients. After antipsychotic treatment the serum concentrations of AEA and OEA were both reduced in SCZ patients [77]. Jónasdóttir and co-workers developed a LC-MS/MS platform for the analysis of 36 specialized proresolving lipid mediators.…”

Section: Human Serum Plasma Blood and Csfmentioning

confidence: 99%

Quantification of Eicosanoids and Their Metabolites in Biological Matrices: A Review

2018

View full text Add to dashboard Cite

The quantification of eicosanoids and their metabolites in biological samples remain an analytical challenge, even though a number of methodologies/techniques have been developed. The major difficulties encountered are related to the oxidation of eicosanoids and their low quantities in biological matrices. Among the known methodologies, liquid chromatography-mass spectrometry (LC-MS/MS) is the standard method for eicosanoid quantification in biological samples. Recently advances have improved the ability to identify and simultaneous quantitate eicosanoids in biological matrices. The present article reviews the quantitative analysis of eicosanoids in different biological matrices by LC and ultra performance liquid chromatography (UPLC)-MS/MS and discusses important aspects to be considered during the collection, sample preparation and the generation of calibration curves required for eicosanoid analysis.

show abstract

Alterations of eicosanoids and related mediators in patients with schizophrenia

Cited by 23 publications

References 67 publications

Soluble Epoxide Hydrolase Inhibitor: A Novel Potential Therapeutic or Prophylactic Drug for Psychiatric Disorders

Soluble Epoxide Hydrolase Inhibitor: A Novel Potential Therapeutic or Prophylactic Drug for Psychiatric Disorders

Metabolomics Biomarkers for Precision Psychiatry

Quantification of Eicosanoids and Their Metabolites in Biological Matrices: A Review

Contact Info

Product

Resources

About